BLLN BillionToOne, Inc.
Company Analysis
Latest News
🔴 BillionToOne is trading 4.24% down today amid biotech-sector weakness
BillionToOne is trading at $98.37, down 4.24%, with biotech-sector weakness the clearest available context. - No new company-specific announcement explaining...
🟢 BillionToOne is trading 4.15% up with no clear company-specific catalyst
BillionToOne is trading 4.15% higher at $101.94 on October 15, 2026, with no clear company-specific announcement explaining the move. - The latest company...
BillionToOne's Cancer Test Clears a Major Hurdle — But Can the Stock Price Catch Up to the Science?
Shares of BillionToOne barely budged at $94.30 despite the company announcing that its liquid biopsy cancer detection test cleared every primary and secondary...
BillionToOne Reports Positive Pivotal Results for Cancer Detection Test
BillionToOne, Inc. announced positive topline results from a pivotal registrational trial of its liquid biopsy test for early cancer detection. The study met...
🟢 BillionToOne is trading 4.03% up
BillionToOne is trading at $98.25, up 4.03%, with no clear catalyst identified for the gain. - No clear company-specific catalyst explaining the October 14...
🔴 BillionToOne is trading 4% down
BillionToOne is trading 4.02% lower at $94.15; no clear company-specific catalyst for the October 12 move surfaced in reviewed coverage. - The latest company...
🟢 BillionToOne rises 4.9% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 BillionToOne is trading 4% down with no clear company-specific catalyst
BillionToOne is trading 4.01% down at $91.91 on October 8, 2026; no clear company-specific catalyst has been identified. - Its latest announcement, published...
🔴 BillionToOne is trading 5% down today as equities fall, oil and Treasury yields rise
BillionToOne is trading at $95.00, down 4.94%, amid broader market pressure. - On October 7, 2026, equities fell, oil and Treasury yields rose, and investors...
🔴 BillionToOne is trading 5% down; no confirmed company-specific catalyst
BillionToOne is trading 5.24% down at $103.34 on October 6, 2026, with no confirmed company-specific announcement explaining the decline. - Recent coverage...
🔴 BillionToOne is trading 10.14% down with no confirmed catalyst identified
BillionToOne is trading 10.14% down at $106.20 on September 30, 2026, with no clear company-specific announcement or confirmed catalyst for the decline found...
🔴 BillionToOne is trading 4.7% down; immediate catalyst remains unclear
BillionToOne is trading at $112.64, down 4.68%, as its immediate catalyst remains unclear. - No clear new company-specific announcement explaining the...
🟢 BillionToOne is trading 10% up today on an unattributed move
BillionToOne is trading 10% higher at $125.98 on an unattributed trading move. - No clear company-specific announcement or event dated September 24, 2026...
🟢 BillionToOne is trading 5% up today despite biotech and broader-market weakness
BillionToOne is trading 5.19% higher at $120.36, with no new company announcement or clearly attributable catalyst identified. - The advance comes despite...
🟢 BillionToOne is trading 10.23% up today amid XBI’s 2.07% gain
BillionToOne is trading 10.23% up now at $114.49, supported by broader biotech-sector strength, while no clear company-specific announcement has been...
🟢 BillionToOne is trading 4.18% up today — catalyst remains unclear
BillionToOne is trading 4.18% up at $108.20 on September 22, 2026; no company-specific announcement directly explaining the gain was identified. - General...
🔴 BillionToOne is trading 4.03% down today after CEO sold his entire directly held stake
BillionToOne is trading 4.03% down at $106.21 after disclosure that CEO Oguzhan Atay sold 30,331 shares worth approximately $3 million on September 14,...
🟢 BillionToOne rises 4.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 BillionToOne is trading 4.48% up today despite weaker broader-market and biotech conditions
BillionToOne is trading 4.48% up at $105.34 despite weaker broader-market and biotech-sector conditions on September 15, 2026; no company-specific announcement...
BillionToOne Executives Sell $2.1M in Stock, as Growth Concerns Hit Shares
BillionToOne, Inc. executives sold significant company stock on September 12, 2026. Chief Technology Officer David Tsao sold shares valued at approximately...